
Optimi Health Debuts Standardized Psilocybin Microdoses for Research
Vancouver-based pharmaceutical manufacturer Optimi Health Corp. has launched two new standardized psilocybin drug products at 1mg and 2mg dosages. By providing consistent, naturally derived formulations, the company aims to eliminate the potency variations common in raw mushroom samples that have historically complicated controlled clinical trials and psychological research.






















